Market Research Report
Biodefense Market, By Product (Smallpox, Anthrax, Radiation/Nuclear, Botulism, Detectors/Triggering Devices, Samplers, Identifiers, Assays, & Reagents), & Geography-Analysis, Share, Trends, Size, & Forecast from 2019-2025
|Published by||AnalystView Market Insights||Product code||918917|
|Published||Content info||159 Pages
Delivery time: 2-3 business days
|Biodefense Market, By Product (Smallpox, Anthrax, Radiation/Nuclear, Botulism, Detectors/Triggering Devices, Samplers, Identifiers, Assays, & Reagents), & Geography-Analysis, Share, Trends, Size, & Forecast from 2019-2025|
|Published: December 1, 2019||Content info: 159 Pages||
Biodefense Market was valued at USD 5.42 billion by 2018, growing with 4.8% CAGR during the forecast period, 2019-2025
Biodefense is defined as the actions designed to counter biological threats, and prepare to respond bio-incidents. It also refers to the short term, usually military measures to restore biosecurity. Biodefense constitutes the use of medical measures in order to protect individuals against bioterrorism. Biodefense applied to two distinct target populations that are military combatant (troops in the field), and civilian non-combatant.
The market growth is majorly driven by favorable government initiatives. Organizations such as Centers for Disease Control and Prevention (CDC), the Department of Defense (DoD), Biomedical Advanced Research and Development Authority (BARDA), and the United States Department of Health & Human Services (HHS) are actively working towards medical countermeasures against such biological threats. Such initiatives would, in turn, support the market growth to a great extent. However, strict regulations coupled with high barriers to entry will hamper the market growth to some extent.
The product segment is broadly classified into vaccines and biothreat detection devices. Vaccine products are further divided into Smallpox, Anthrax, Radiation/nuclear, Botulism, and others. Anthrax and smallpox are amongst the key areas for R&D activities due to their high potential for destruction. These products are continuing to command the attention of many governments globally, accounting for a significant share of the worldwide market. Of these, anthrax captured the highest revenue share, i.e. over 30% in 2018 owing to the rising investments by the U.S. government for mitigating the anthrax bioterrorism risk. Currently, Anthrax Vaccine Adsorbed (AVA) is the only U.S. FDA licensed anthrax vaccine, commercially available under BioThrax trade name in the U.S. market.
Whereas, biothreat detection devices segment is categorized into detectors/triggering devices, samplers, identifiers, assays, and reagents. Biodefense samplers are primarily used to facilitate biological sampling as well as for the transport packaging, reducing waste and speeding up sampling time.
North America captured the highest share (more than 70%) of the worldwide biodefense market. Rising financial support by the U.S. military and civilian agencies for R&D activities coupled with favorable government policies support the regional growth. For instance, the U.S. government has taken steps to implement an enterprise approach and integrated strategy to combat biological threats. In September 2018. U.S. President Donald J. Trump has suggested implementing a National Biodefense Strategy to effectively prepare for fighting biological threats.
On the other side, developing regions such as the Asia Pacific accounts for significant revenue share. Regional growth is majorly attributed to the rising government support coupled with the growing number of conferences on biosafety. For instance, in September 2019, Asia Pacific Biosafety Association (A-PBA) has organized the 14th Annual Biorisk Conference in Dhaka, Bangladesh. This conference was aimed to discuss proactive steps on biosafety and biosecurity for the sustainable development of a region in the healthcare and agricultural sectors.
Key players operating in the global biodefense market include Achaogen, Inc., Xoma Corporation, Emergent BioSolutions, Inc., SIGA Technologies, Inc., PharmAthene, Inc., Elusys Therapeutics, Inc., Dynavax Technologies, Ichor Medical Systems, Cleveland Biolabs, Dynport Vaccine Company, Nanotherapeutics, Inc., Bavarian Nordic, and Alnylam Pharmaceuticals, Inc.
Companies are actively engaged in mergers and acquisitions to expand their presence in the biodefense industry. For instance, a biopharmaceutical company, "Altimmune" acquired PharmAthene, Inc., a biodefense firm in May 2017. This collaboration is aimed to create a new immunotherapy company focused on developing products for infectious diseases such as anthrax. Such activities would, in turn, help key players to expand their presence in this industry.
The market size and forecast for each segment and sub-segments has been considered as below:
The scope of this report covers the market by its major segments, which include as follows: